> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Flags Novo Nordisk Over ‘Misleading’ Wegovy TV Spot
- URL: https://www.fdaweb.com/fda-flags-novo-nordisk-over-misleading-wegovy-tv-spot/
- Published: 2026-02-09T12:00:00.000Z
- Updated: 2026-09-14T15:32:52.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160628

FDA has formally told Novo Nordisk that a new direct-to-consumer (DTC) television ad for the newly launched Wegovy (semaglutide) oral weight-loss pill contains claims that could be “false or misleading,” placing fresh regulatory scrutiny on one of the pharmaceutical industry’s highest-profile product launches. In a [2/5 untitled letter](https://www.fda.gov/media/191020/download?attachment&ref=fdaweb.com), CDER’s Office of Prescription Drug Promotion (OPDP) says the DTC ad misbrands **Wegovy** in violation of the Federal Food, Drug, and Cosmetic Act because it implied benefits that arenot supported by available evidence.

The ad’s use of phrases such as “live lighter” and “a way forward” misleadingly suggests that because of its dosage form (i.e., pill), Wegovy offers an advancement or improvement (i.e., superior efficacy and/or safety) over other currently approved glucagon-like peptide-1 (GLP-1) treatments for weight loss. “Specifically, these claims and presentations misleadingly imply that Wegovy in pill form uniquely enables patients to achieve outcomes that were not previously possible with other GLP-1 treatments for weight loss,” the letter says. It also says the claims “misleadingly imply additional weight loss compared to other currently approved GLP-1 treatments, when this has not been demonstrated. Additionally, they misleadingly imply benefits beyond physical weight loss such as emotional relief, reduced psychological burden, hope, or direction for patients’ lives, positioning the drug as a solution to broader life challenges rather than a treatment for a specific condition, when this has also not been demonstrated.”

Novo Nordisk only recently began shipping the Wegovy pill in the U.S. after FDA approved it in December as the first once-daily oral GLP-1 therapy for weight management, based on Phase 3 data showing statistically significant weight loss versus placebo. The OPDP letter notes that the company’s data does not support comparative superiority claims, not does it support positioning the pill as uniquely enabling outcomes “not previously possible.”

In addition to the broader messaging concerns, the agency told Novo Nordisk that the ad’s major statement “includes presentations where there is information in the SUPERs that is not from the corresponding audio. Therefore, the TV ad is misleading because it fails to present the major statement concurrently using both audio and text (dual modality).”

Following standard OPDP actions, the letter requests that the company cease distribution of the misleading promotional materials and provide a written corrective plan within 15 working days, outlining how the company will address the issues raised.